Here, we demonstrated that LINC00022 promoted cell cycle progression of ESCC cells by affecting a series of cell cycle regulators including p16, p21, p53, CDK2 and Cyclin E1. This evidence concerns the gene CDK2 and esophageal squamous cell carcinoma.